Secondly, more bladder cancer cohorts are needed to prove the possibility of OLFML2B as a marker, and more in-depth mechanism experiments are needed to prove the carcinogenicity of OLFML2B. This evidence concerns the gene OLFML2B and urinary bladder carcinoma.